[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652196":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":51,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":83,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":11},{"fullName":5,"class":6},"University Hospital, Gentofte, Copenhagen","OTHER",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Vehicle","PLACEBO_COMPARATOR",null,[13,14],"Other: Placebo: First dose at 0 hours","Other: Liquid meal and second dose of placebo at 3 hours",{"label":16,"type":17,"description":11,"interventionNames":18},"ARA-T","EXPERIMENTAL",[19,20],"Other: Arachidonoyl-taurine: First dose at 0 hours","Other: Liquid meal and second dose of ARA-T at 3 hours",{"label":22,"type":17,"description":11,"interventionNames":23},"OLE-T",[24,25],"Other: Oleoyl-taurine: First dose at 0 hours","Other: Liquid meal and second dose of OLE-T at 3 hours",[27,31,35,39,43,47],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Placebo: First dose at 0 hours","Vehicle (ultrapure water with 10 % fish sauce), orally administered",[9],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Arachidonoyl-taurine: First dose at 0 hours","Arachidonoyl-taurine (2 mg\u002Fkg) dissolved in ultrapure water with 10 % fish sauce, orally administered",[16],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"Oleoyl-taurine: First dose at 0 hours","Oleoyl-taurine (2 mg\u002Fkg) dissolved in ultrapure water with 10 % fish sauce, orally administered",[22],{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"Liquid meal and second dose of placebo at 3 hours","Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Vehicle (ultrapure water with 10 % fish sauce), orally administered",[9],{"type":6,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"Liquid meal and second dose of OLE-T at 3 hours","Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Oleoyl-taurine (2 mg\u002Fkg) dissolved in ultrapure water with 10 % fish sauce, orally administered",[22],{"type":6,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"Liquid meal and second dose of ARA-T at 3 hours","Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Arachidonoyl-taurine (2 mg\u002Fkg) dissolved in ultrapure water with 10 % fish sauce, orally administered",[16],{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Asger Lund, MD","Associate Professor, MD, PhD",[56],{"name":57,"class":6},"University of Copenhagen","100652196","effects-of-n-acyl-taurines-on-incretin-levels-in-healthy-subjects-100652196",false,"NCT07771166","Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects","Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects: a Randomised, Double-blind, Placebo-controlled, Cross-over Study","NAT-INC","Inclusion Criteria:\n\n* Age between 18 and 45 years\n* Body mass index between 18.5-27 kg\u002Fm2\n* Informed consent\n* Weight stable in the past 3 months\n\nExclusion Criteria:\n\n* Regular tobacco smoking or use of other nicotine-containing products\n* Allergy or intolerance to ingredients included in the test compounds or standardised meals\n* Glycated haemoglobin (HbA1c) \\>48 mmol\u002Fmol\n* Anaemia (haemoglobin below 8.3 mmol\u002FL)\n* Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>2 times upper normal values (Normal values: ALT \\\u003C 70 U\u002FL, AST \\\u003C45 U\u002FL)\n* Nephropathy (eGFR\\\u003C90mL\u002Fmin\u002F1.73 m2) and\u002For albuminuria (\\>30 mg\u002Fg albumin in urine))\n* Women of childbearing potential who are not using effective contraception\n* Pregnancy or breastfeeding\n* History of hepatobiliary or gastrointestinal disorder(s)\n* Use of weight loss medication within the last 6 months\n* Any physical or psychological condition, or ongoing medication, that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses",true,"ALL","18 Years","45 Years",{"count":71,"type":72},18,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of arachidonoyl-taurine (C20:4-taurine) and oleoyl-taurine (C18:1-taurine) on GLP-1 secretion during fasting and feeding.",[78],"Cardiometabolic Conditions",[80,81,82],"Glucagon-like peptide 1","N-acyl taurine","GPR119","NOT_YET_RECRUITING","2026-08-13",{"date":86,"type":87},"2026-08-18","ACTUAL",{"date":89,"type":72},"2027-06",{"date":91,"type":72},"2028-12",{"name":5,"class":6}]